#ECFS2018 – Potential CFTR Corrector PTI-801, Plus Orkambi, Seen to Treat CF Patients in Phase 1 Trial Jun 08, 2018 10:30 am | Patricia Inacio, PhD

Treatment for 14 days with Proteostasis Therapeutics’ PTI-801 in cystic fibrosis (CF) patients also being treated with Orkambi (lumacaftor/ivacaftor) led to statistically significant improvements in sweat chloride, body mass index, and rescued blood glucose levels in a subgroup of patients with diabetes, Phase 1 trial data show. PTI-801 is being tested in a 14-day study in adults with […] The post #ECFS2018 – Potential CFTR Corrector PTI-801, Plus Orkambi, Seen to Treat CF Patients in Phase 1 Trial appeared first on Cystic Fibrosis News Today.

Read More

#ECFS2018 – Potential CFTR Corrector PTI-801, Plus Orkambi, Seen to Treat CF Patients in Phase 1 Trial

JUNE 8, 2018

BY PATRICIA INACIO, PHD

 

IN CYSTIC FIBROSIS, NEWS.